Currently, there are 149.57M common shares owned by the public and among those 148.55M shares have been available to trade.
The company’s stock has a 5-day price change of 10.76% and -8.72% over the past three months. CC shares are trading -46.51% year to date (YTD), with the 12-month market performance down to -26.92% lower. It has a 12-month low price of $9.13 and touched a high of $25.54 over the same period. CC has an average intraday trading volume of 4.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.86%, 9.52%, and -22.80% respectively.
Institutional ownership of Chemours Company (NYSE: CC) shares accounts for 97.00% of the company’s 149.57M shares outstanding.
It has a market capitalization of $1.85B and a beta (3y monthly) value of 1.63. The stock’s trailing 12-month PE ratio is 60.01, while the earnings-per-share (ttm) stands at $0.21. The company has a PEG of 1.86 and a Quick Ratio of 0.83 with the debt-to-equity ratio at 7.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.32% over the week and 5.70% over the month.
Analysts forecast that Chemours Company (CC) will achieve an EPS of 0.48 for the current quarter, 0.55 for the next quarter and 2.44 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.38 while analysts give the company a high EPS estimate of 0.38. Comparatively, EPS for the current quarter was 0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 29.39%, and 56.36% over the next financial year.
Looking at the support for the CC, a number of firms have released research notes about the stock. Mizuho stated their Outperform rating for the stock in a research note on March 27, 2025, with the firm’s price target at $19. Truist coverage for the Chemours Company (CC) stock in a research note released on January 28, 2025 offered a Buy rating with a price target of $27. UBS was of a view on July 09, 2024 that the stock is Buy, while Mizuho gave the stock Neutral rating on June 07, 2024, issuing a price target of $25. BMO Capital Markets on their part issued Outperform rating on April 09, 2024.
